MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$3,855K
EPS
-$0.35
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development, net
963
762
1,147*
899
General and administrative
2,650
1,284
1,742*
1,148
Operating loss
-3,613
-2,046
-2,888*
-2,047
Financial income (expense), net
-242
-81
51*
-59
Gain on change in fair value of warrants liability (note 7)
-
-
-45*
-
Net loss
-3,855
-2,127
-2,793
-2,106
Basic EPS
-0.35
-0.19
-0.342
-0.19
Diluted EPS
-0.35
-0.19
-0.342
-0.19
Basic Average Shares
11,034,775
11,034,775
8,178,481
11,008,047
Diluted Average Shares
11,034,775
11,034,775
8,178,481
11,008,047
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$3,855K
(-32.79%↓ Y/Y)
Operating loss
-$3,613K
(-40.42%↓ Y/Y)
Financial income
(expense), net
-$242K
(26.67%↑ Y/Y)
General and
administrative
$2,650K
(82.38%↑ Y/Y)
Research and
development, net
$963K
(-14.02%↓ Y/Y)
Buy us a coffee
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)